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Abstract: Restless legs syndrome (RLS) is a common neurological disorder characterized by 
an irresistible urge to move the legs accompanied by uncomfortable sensations that occur at 
night or at time of rest. Pharmacological therapy should be limited to patients who suffer from 
clinically relevant symptoms. Chronic RLS is usually treated with either a dopamine agonist 
(pramipexole, ropinirole, rotigotine) or an α
2
δ calcium-channel ligand (gabapentin, gabapentin 
enacarbil, pregabalin). Augmentation is the main complication of long-term dopaminergic 
treatment, and frequently requires a reduction of current dopaminergic dose or a switch to non-
dopaminergic medications. Opioids as monotherapy or add-on treatment should be considered 
when alternative satisfactory regimens are unavailable and the severity of symptoms warrants 
it. In a recent Phase III trial, oxycodone–naloxone prolonged release (PR) demonstrated a 
significant and sustained effect on patients with severe RLS inadequately controlled by previ-
ous treatments. The adverse-event profile was consistent with the safety profile of opioids. 
The most frequent adverse events were fatigue, constipation, nausea, headache, hyperhidrosis, 
somnolence, dry mouth, and pruritus. Adverse events were usually mild or moderate in intensity. 
No cases of augmentation were reported. Oxycodone–naloxone PR is approved for the second-
line symptomatic treatment of adults with severe to very severe idiopathic RLS after failure of 
dopaminergic treatment. Further studies are needed to evaluate if oxycodone–naloxone PR is 
equally efficacious as a first-line treatment. Moreover, long-term comparative studies between 
opioids, dopaminergic drugs and α
2
δ ligands are needed.
Keywords: augmentation, dopamine, oxycodone–naloxone, restless legs syndrome
Introduction
Restless legs syndrome (RLS) is a common neurological disorder characterized by 
an irresistible urge to move the legs accompanied by uncomfortable sensations that 
occur at night or at time of rest.1 According to the 2012 revised criteria, diagnosis is 
based on the presence of the following five criteria: 1) an urge to move the legs, usu-
ally accompanied or caused by uncomfortable and unpleasant sensations in the legs; 
2) the urge to move begins or worsens during periods of rest or inactivity, such as 
lying or sitting; 3) the urge to move is partially or totally relieved by movement, such 
as walking or stretching, at least as long as the activity continues; 4) the urge to move 
is worse in the evening or at night than during the day or only occurs in the evening 
or night; and 5) the symptoms cannot be attributed to another medical condition (eg, 
leg edema, arthritis, leg cramps) or behavioral condition (eg, positional discomfort, 
habitual foot tapping).2 Approximately 80%–85% of patients with RLS have periodic 
and involuntary stereotyped jerks in the lower limbs, known as periodic limb move-
ments (PLMs).3 Not surprisingly, RLS patients may complain of disruption of sleep, 
insomnia, and sleepiness during the day. RLS can have a serious impact on quality 
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of life. Compared to the general population, RLS patients 
present a higher incidence of anxiety and depression.4
RLS is common in the general population, with a 
prevalence of 5%–10%.5 Approximately 2%–3% of adults 
have clinically significant symptoms, occurring at least twice 
a week and reported as moderately or severely distressing.4 
Prevalence has been observed to rise with age, and is higher 
in women than in men.6
Primary and secondary forms of RLS are recognized. 
A large proportion of patients (70%–80%) are affected by 
the primary form of RLS. Primary RLS usually has an earlier 
onset (,45 years old), slower development, and a strong 
familial link.7 To diagnose a primary form of RLS, all the 
known causes of secondary forms of the disease should be 
excluded.8–13 Symptomatic forms of RLS may improve or 
disappear upon treating the underlying disorder.
The precise pathogenesis of RLS is still unknown, 
but dysfunctional dopaminergic modulation of neuronal 
excitability is generally thought to be the main underlying 
pathophysiological mechanism of RLS, as suggested by the 
positive response to dopaminergic agents in patients with 
RLS.14 However, there is increasing evidence that interac-
tion with other transmitter systems, such as opioids and the 
γ-aminobutyric acid-ergic system, as well as iron deficiency, 
is crucial for the manifestation of RLS symptoms.15
Pharmacological therapy should be limited to those 
patients who suffer from clinically relevant symptoms. 
Levodopa is used as on-demand treatment in intermittent RLS, 
but because of its short half-life (t
½
), patients often encounter 
symptom rebound.16 The long-term use of levodopa often 
reveals tolerance and a typical complication called augmenta-
tion. Augmentation refers to the worsening of RLS-symptom 
severity from pretreatment levels following an initial benefit, 
with an earlier onset of symptoms by at least 2–4 hours, often 
associated with a shorter latency to RLS symptoms at rest, 
extension of symptoms to other body parts, and increased 
intensity of symptoms.17
Chronic RLS should be treated with either a nonergot 
dopamine agonist (pramipexole, ropinirole, rotigotine) or 
an α
2
δ calcium-channel ligand (gabapentin, gabapentin 
enacarbil, pregabalin). Short-term adverse effects due 
to treatment with dopamine agonists are gastrointesti-
nal disturbances, weight gain, dizziness, sedation, and 
impulse-control disorders, while the main complication 
of long-term dopaminergic treatment is augmentation. 
Although less common than with levodopa, augmentation 
represents the main challenge in RLS treatment. The use 
of α
2
δ calcium-channel ligands should be considered for 
initial treatment of RLS patients with comorbid insomnia, 
anxiety, or comorbid pain.18
In refractory RLS, combination treatment should be 
considered for patients with symptoms that cannot be con-
trolled with a low-dose monotherapy of either treatment 
class. Second agents may include a dopamine agonist for 
patients treated with an α
2
δ ligand or vice versa, or an opi-
oid.19 Opioids as monotherapy or add-on treatment should 
be considered when alternative satisfactory regimens are 
unavailable and the severity of symptoms warrants it.
In a recent study, oxycodone–naloxone prolonged release 
(PR) was demonstrated to be efficacious in the treatment of 
RLS not adequately controlled with previous treatments.20 
The positive response to opioid treatment suggests that the 
hypofunction of the endogenous opioid system might be 
pathogenetic in RLS. This hypothesis has been investigated in 
a study showing that the signs and symptoms of RLS reappear 
in opioid-treated patients given intravenous naloxone.21
In 2015, Targin®, a fixed combination of oxycodone–
naloxone PR, received a positive European Commission 
decision as second-line symptomatic treatment for patients 
with severe to very severe idiopathic RLS after failure of 
dopaminergic therapy.22
The aim of this review is to describe the pharmacological, 
clinical, and tolerability properties of oxycodone–naloxone PR 
in the treatment of RLS. This is based on a literature search using 
the PubMed database from 1986 to 2015. The search terms 
were: oxycodone–naloxone, opioid, restless legs syndrome, 
augmentation, and pharmacokinetics. References from identi-
fied articles and abstracts from meetings were also reviewed.
Overview and pharmacological data
Oxycodone (6-deoxy-7,8-dihydro-14-hydroxy-3-O-methyl-
6-oxomorphine) is a semisynthetic opioid developed from 
the opium derivative, thebaine.23 Oxycodone is a μ-, κ-, and 
δ-receptor opioid agonist whose principal therapeutic action is 
pain relief. It also binds to gut opioid receptors, inducing consti-
pation. The use of oxycodone has increased in recent years, and 
it has replaced morphine as the most used opioid among general 
practitioners, as well as among hospital physicians.23 Naloxone 
is a semisynthetic competitive opioid antagonist that acts locally 
on the gut, counteracting opioid-induced constipation (OIC). 
It has a very high affinity for opioid receptors, and displaces 
opioid agonists. After systemic administration, it reverses both 
centrally and peripherally mediated opioid effects.24
Following oral administration, oxycodone displays 
high oral bioavailability (60%–87%). The presence of 
a CH
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Prolonged-release oxycodone–naloxone in RLS treatment
the oxycodone molecule in comparison to morphine is 
responsible for reduced first-pass metabolism and thus greater 
bioavailability.25 Oxycodone is available in immediate-
release (IR) and PR formulations. Today, oxycodone is 
mainly used as PR tablets for chronic pain. The IR tablets 
are used for acute pain or for breakthrough pain.26
The absorption profile of the PR tablet is best described 
using a biexponential absorption model, with a rapid ini-
tial absorption component (t
½
 of absorption 37 minutes) 
accounting for 38% of the available dose, followed by a 
slow-absorption phase (t
½
 of absorption 6.2 hours) account-
ing for 62% of the available dose.27
Maximum plasma concentration is reached within 1.3 hours 
after IR administration and 2.6 hours after administration of a 
PR formulation.26 The maximum plasma concentration after 
IR oxycodone administration is twice as high as an equivalent 
dose of PR oxycodone.27 The PR preparations are bioequiva-
lent to IR preparations, allowing dosing every 12 hours.28 
Food has no significant effect on the extent of absorption of 
oxycodone. Naloxone possesses low bioavailability after oral 
administration (,3%), because of extensive first-pass hepatic 
metabolism. As a result, naloxone acts almost exclusively on 
opioid receptors in the gastrointestinal tract.29 A pharmacoki-
netic study demonstrated that coadministration of oxycodone 
PR and naloxone PR in fixed doses did not significantly affect 
the bioavailability of either of its constituents.30 The optimal 
2:1 ratio of PR oxycodone:PR naloxone was demonstrated in a 
Phase II study, rendering effective analgesia and improvement 
in bowel function with good treatment tolerance in patients 
with severe chronic pain.31,32
Oxycodone is approximately 45% bound to plasma 
proteins (mainly albumin) in a non-dose-dependent man-
ner and is widely distributed throughout the body, with an 
apparent volume of distribution of approximately 2–3 L/kg.33 
Oxycodone and naloxone pass into the placenta. Oxycodone–
naloxone is contraindicated during pregnancy, labor, and 
delivery, due to impaired uterine contractility and the risk 
of neonatal respiratory depression. Oxycodone passes into 
the breast milk. It is not known whether naloxone is excreted 
in human milk. Since the safety of oxycodone–naloxone in 
infants and newborns has not been studied, it is contraindi-
cated in nursing mothers.34
Oxycodone is mostly metabolized in the liver to noroxy-
codone via CYP3A4 and to a lesser extent to oxymorphone 
through CYP2D6; both noroxycodone and oxymorphone are 
subsequently converted to noroxymorphone via CYP2D6 and 
CYP3A4, respectively.35 The primary oxycodone metabolites 
(noroxycodone and oxymorphone) also display affinity for 
μ-opioid receptors. However, noroxycodone possesses only 
17% of the potency of the parent compound, while oxymor-
phone, in spite of high affinity for μ-opioid receptors, is 
produced in very small amounts.36 Therefore, it is oxycodone 
itself that produces the analgesic effects of the opioid.
Noroxymorphone is produced in significant amounts and 
possesses significant affinity for opioid receptors. However, 
the blood–brain barrier is extremely impermeable to noroxy-
morphone in comparison to the parent compound, and thus 
its role in analgesia seems to be negligible.37
Although no clinical studies have been conducted, 
CYP3A4 inhibitors (eg, ketoconazole, ritonavir) may cause 
decreased clearance of oxycodone and increased plasma 
concentrations, with greater risk of toxicity. CYP3A4 
inducers (eg, rifampin, carbamazepine) may cause increased 
clearance of the drug, which could lead to a decrease in 
oxycodone plasma concentrations, lack of effect, or possibly 
the development of an abstinence syndrome.34 Oxycodone is 
only partially metabolized via the hepatic CYP2D6 pathway; 
concomitant administration of CYP2D6 inhibitors has not 
been shown to be of clinical significance during oxycodone 
treatment.34 However, the concurrent use of CYP3A4 
and CYP2D6 inhibitors can further affect oxycodone 
metabolism.38 A pharmacodynamic interaction of oxycodone 
with other drugs acting on the central nervous system, such 
as benzodiazepines, neuroleptics, and antidepressants, may 
intensify oxycodone adverse effects, especially sedation, and 
respiratory depression in patients that are more sensitive to 
opioids.34 Considering that naloxone possess low bioavail-
ability after oral administration (,3%), the potential for 




 of oxycodone is approximately 3 hours after 
administration with an IR solution and approximately 8 hours 
after PR tablets. Oxycodone is mainly excreted in urine after 
metabolism, with limited amounts excreted as unchanged 
drug.28 The main properties and pharmacokinetic parameters 
of oxycodone–naloxone PR are summarized in Table 1.
Oxycodone elimination is impaired with renal failure, 
due to an increased volume of distribution and reduced 
clearance. Patients with impaired renal function (creatinine 
clearance ,60 mL/min) and patients with mild-to-moderate 
hepatic dysfunction showed peak plasma oxycodone and 
noroxycodone concentrations 50% and 20% higher, respec-
tively, than normal subjects. Oxycodone–naloxone PR 
should be used with caution in these populations, while it is 
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Opioids and restless legs syndrome
Most patients with RLS initially respond well to dopaminer-
gic agonists. Although initially effective, long-term dopamin-
ergic treatment can result in loss of efficacy, difficulties with 
tolerability, or augmentation, necessitating a change of drug 
regimen. Before the study that gave the basis for the approval 
of oxycodone–naloxone PR as second-line symptomatic 
treatment for patients with severe to very severe idiopathic 
RLS after failure of dopaminergic therapy, opioids were used 
as off-label second-line treatment to treat severe RLS with 
no responsivity to first-line treatment.20,22 The efficacy and 
tolerability of opioids for the treatment of RLS have been 
investigated in few studies.39–48
In a 10-year longitudinal assessment, methadone, a long-
acting μ-opioid agonist, has demonstrated a persistent effect. 
Methadone showed no augmentation with continued efficacy 
after the first year of treatment. Approximately 15% of the 
76 patients who were started on methadone in the first year 
discontinued due to lack of efficacy or side effects (eg, seda-
tion, depression, and anxiety), but none discontinued it after 
the first year.39 On the other hand, patients on treatment with 
pramipexole showed annual rates for discontinuing treatment 
of 9% after the first year, with annual augmentation rates 
of 7% compared to 0 for methadone. The medium dose of 
methadone at 6 months was 10 mg, and increased by ,10 mg 
after 8–10 years on this drug.39
In a retrospective case-series, of the initial 27 RLS 
patients in that study, 17 were still on methadone for an aver-
age duration of use of 22.9±12 months (range: 4–44 months). 
All of the dropouts occurred in the first 12 months of use 
(five for adverse events, two for lack of efficacy, and one for 
logistical reasons). All patients who remained on methadone 
reported at least a 75% reduction in symptoms, and none 
developed augmentation.40
In a double-blind randomized crossover trial, oxycodone 
or placebo was given in divided nighttime doses to eleven 
patients with idiopathic RLS for 2 weeks before appropriate 
polysomnographic studies. Leg sensations, motor restless-
ness, and daytime alertness were significantly improved on 
oxycodone compared to baseline or placebo. On an aver-
age dose of 15.9 mg oxycodone, there was a statistically 
significant reduction in the number of PLMs/hour of sleep 
Table 1 Main properties and pharmacokinetic parameters of oxycodone–naloxone PR
Mechanism of action Oxycodone is a μ-, κ-, and δ-receptor opioid agonist. Naloxone is a competitive opioid antagonist that 
acts locally on the gut, counteracting the opioid-induced constipation
Starting dose (for RLS) 5 mg/2.5 mg oxycodone/naloxone BiD
Therapeutic dose (for RLS) Up to 60 mg/30 mg oxycodone/naloxone daily
Dosing schedule BiD
Absorption Oral administration, biexponential absorption with a rapid component (t½ absorption 37 minutes) 
accounting for 38% of the dose, and a slow-absorption phase (t½ absorption 6.2 hours) accounting 
for 62% of the available dose; oxycodone bioavailability 60%–87%; can be given without regard to meals
Distribution Apparent volume of distribution 2–3 L/kg; 45% bound to plasma proteins
Metabolism Oxycodone is mostly metabolized in the liver to inactive noroxycodone via CYP3A4 and to a 
lesser extent to active oxymorphone through CYP2D6; both noroxycodone and oxymorphone are 
subsequently converted to noroxymorphone via CYP2D6 and CYP3A4, respectively
interactions CYP3A4 inhibitors may cause decreased clearance of oxycodone and an increase in its plasma 
concentrations. CYP3A4 inducers may cause increased clearance of the drug, which could lead 
to a decrease in oxycodone plasma concentrations, lack of effect, or possibly the development of 
an abstinence syndrome. Other drugs acting on the CNS, such as benzodiazepines, neuroleptics, 
and antidepressants, may intensify oxycodone adverse effects, especially sedation, and respiratory 
depression in patients that are more sensitive to opioids
elimination Mainly excreted in urine, with limited amounts of oxycodone excreted as unchanged drug; t½ is 4.5 hours
Abbreviations: PR, prolonged release; RLS, restless legs syndrome; BiD, bis in die (twice a day); t½, half-life; CNS, central nervous system.
Table 2 Oxycodone–naloxone PR in special populations
Renal impairment Should be used with caution in patients with 
impaired renal function
Hepatic impairment Should be used with caution in patients with mild 
hepatic dysfunction; contraindicated in patients 
with moderate and severe hepatic impairment
Pregnancy, labor,  
and delivery
Contraindicated during pregnancy, labor, and 
delivery, due to impaired uterine contractility 
and the risk of neonatal respiratory depression
Nursing women Safety in infants and newborns has not been 
studied; therefore, it is contraindicated in nursing 
mothers
Pediatric population Safety and effectiveness in pediatric patients not 
established
Geriatric population Dosage should be adjusted to the lowest dose, 
which will achieve satisfactory symptom relief 
with acceptable side effects
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(P,0.004) and in the number of arousals/hour of sleep 
(P,0.009) on the drug compared to baseline or placebo. The 
authors concluded that oxycodone is an effective treatment 
for RLS and PLMs.41
Tramadol, a centrally acting synthetic opioid-like 
analgesic, was assessed in the management of RLS in an 
open-label study.42 Patients were monitored at follow-up 
visits at a minimum of every 3 months for a mean of 22.8 
(range: 15–26) months. Tramadol dosage ranged from 50 
to 150 mg daily. The difference between pretreatment and 
posttreatment symptom severity was statistically significant 
(P=0.0039). Augmentation has been reported after treatment 
of RLS with tramadol, while it has not been reported with 
other opioids.43,44
Finally, three case series reported on the successful use 
of morphine administered intrathecally via implantable 
pump for the treatment of refractory RLS.45–47 Stopping the 
morphine delivery resulted in unbearable RLS symptoms, 
suggesting that the benefit was probably not the result of a 
placebo effect.48
Clinical efficacy of oxycodone–
naloxone PR in the treatment 
of RLS
The efficacy of oxycodone–naloxone PR in the treatment of 
severe RLS was demonstrated in a Phase III trial that inves-
tigated the efficacy and safety of oxycodone–naloxone PR in 
patients with severe RLS inadequately controlled by previous, 
mainly dopaminergic, treatments.20 This multicenter study 
consisted of a 12-week randomized, double-blind, placebo-
controlled trial and 40-week open-label extension phase done 
at 55 sites in Austria, Germany, Spain, and Sweden.
Patients had symptoms for at least 6 months with an 
International RLS Study Group (IRLSSG) severity-rating 
scale sum score of at least 15 at screening (indicative of at 
least moderate severity). Lack of efficacy of previous drug 
treatment had to be a result of either intolerable side effects 
or insufficient efficacy, according to medical history. Patients 
were excluded if they had secondary RLS, sleep apnea 
syndrome, severe chronic obstructive pulmonary disease, 
narcolepsy, myoclonic epilepsy, hallucinations, or psychotic 
episodes. Patients were withdrawn from any current treatment 
for RLS before entering the study. Patients were randomly 
assigned to oxycodone–naloxone PR twice daily (n=150) or 
placebo (n=154). The starting dose was oxycodone 5 mg, 
naloxone 2.5 mg twice daily, which was increased accord-
ing to investigators’ opinion to a maximum of oxycodone 
40 mg, naloxone 20 mg twice daily. The primary outcome 
was severity of RLS according to IRLSSG severity-rating 
scale sum score at 12 weeks. Mean IRLSSG severity-rating 
scale sum score at randomization was 31.6±4.5. The mean 
change in IRLSSG severity-rating scale sum score at 12 weeks 
was -16.5±11.3 in the oxycodone–naloxone PR group 
and -9.4±10.9 in the placebo group (P,0.0001). At the end 
of 12 treatment weeks, more than half of all patients treated 
with oxycodone–naloxone PR versus less than a third taking 
placebo were IRLSSG severity-rating scale responders (75 out 
of 132 [57%] vs 45 out of 144 [31%]; P,0.0001), defined as 
at least 50% improvement in IRLSSG severity-rating scale 
score. IRLSSG severity-rating scale remitters were defined 
by a sum score of 0 during treatment (symptom-free) or 10 or 
less at the end of maintenance. During the double-blind phase, 
significantly more patients in the oxycodone–naloxone PR 
group than in the placebo group were IRLSSG severity-rating 
scale remitters (42% vs 19%, P,0.001).
Patients who completed the double-blind phase were eli-
gible to enter the open-label extension. Of the 197 patients 
included in the open-label extension, 157 (80%) completed 
40 weeks of treatment. In the extension, all patients started 
on oxycodone 5 mg, naloxone 2.5 mg, twice a day, which 
was uptitrated according to investigators’ opinion to a 
maximum of oxycodone 40 mg, naloxone 20 mg, twice 
a day. A beneficial effect of treatment with oxycodone–
naloxone PR continued throughout the extension phase, 
with an IRLSSG mean sum score of 15.4±11.2 at the 
start compared with 9.7±7.8 at week 40. At the end of the 
extension phase, 43% patients were classified as IRLSSG 
severity-rating scale remitters, and 22% of those patients 
had no symptoms. No cases of augmentation were reported 
in either phase.
The study demonstrated a significant and sustained treat-
ment effect of oxycodone–naloxone PR. The 16.6-point 
reduction on the IRLSSG severity-rating scale sum score 
during the double-blind phase translates into a significant 
clinical improvement from “very severe” at start of treat-
ment to on average “mild” or “moderate” at the end of the 
double-blind phase. This alleviation of symptoms also led to 
significant improvements in some secondary objectives, such 
as subjective quality of sleep and quality of life during the 
double-blind phase, and showed evidence of improvement 
in the extension phase. The data are especially convincing, 
because the study included patients who were refractory to 
other treatments. Such patients would normally be much 
more likely to fail an alternative treatment than patients 
who have not had previous treatment failure.49 Although 
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oxycodone–naloxone PR was similar or greater than that 
reported in previous studies of dopaminergic drugs.50,51
Oxycodone–naloxone PR is approved for the second-line 
symptomatic treatment of adults with severe to very severe 
idiopathic RLS after failure of dopaminergic treatment.22 
The usual starting dose is 5 mg/2.5 mg of oxycodone/
naloxone at 12-hour intervals. Titration on a weekly basis is 
recommended in case higher doses are required. The mean 
daily dose in the pivotal study was 20 mg/10 mg oxycodone/
naloxone. Some patients may benefit from higher daily doses 
up to a maximum of 60 mg/30 mg oxycodone/naloxone. In 
general, the lowest effective dose should be selected.34,52
Safety and tolerability of 
oxycodone–naloxone PR
Oxycodone is an opioid analgesic that has been demonstrated 
to provide effective analgesia in acute and chronic pain.26,29 
However, the primary disadvantage associated with opioid 
treatment is the development of opioid-induced bowel dys-
function (OIBD), which commonly manifests as significant 
constipation.53 OIBD is a consequence of the action of opioids 
on receptors within the gastrointestinal tract, which reduce 
gastrointestinal motility, inhibit secretion, increase absorp-
tion, affect blood flow, and increase anal sphincter tone.53 As 
a result, patients can experience a range of symptoms, with 
constipation the most frequently reported adverse event.54 
The pain and discomfort caused by OIBD can cause patients 
to reduce or even discontinue their opioid therapy.55
Traditional laxatives are prescribed for the prevention 
and treatment of OIBD, particularly for constipation. How-
ever, these possess limited efficacy and display numerous 
adverse effects.56 Moreover, treatment with laxatives should 
be limited to a short period of time.57 Prevention of OIBD is 
considered a more effective therapeutic strategy than merely 
treating the symptoms as they occur.57 The oral coadministra-
tion of opioids and opioid antagonists with limited systemic 
bioavailability is intended to prevent or minimize OIBD 
without reducing the central analgesic effects of the opioid, 
thanks to the lack of systemic activity.58
In a Phase III, double-blind, randomized controlled 
clinical trial, patients receiving a fixed combination of 
oxycodone–naloxone PR experienced significant improve-
ments in OIC compared with those receiving oxycodone PR, 
with comparable analgesia.59
Meissner et al reported a randomized, double-blind study 
that assessed analgesic efficacy and impact on the OIC of 
oxycodone–naloxone, and identified the optimal dose ratio 
of oxycodone and naloxone.31 A total of 202 patients with 
chronic pain (most nonmalignant, 2.5% cancer-related pain) 
and a stable oxycodone dose (40, 60, or 80 mg/day) were 
randomized into groups that received 10, 20, and 40 mg of 
naloxone daily or placebo. No loss of analgesia with naloxone 
PR was observed. Bowel function improved with increasing 
controlled-release naloxone dose. In a quadratic response-
surface model with naloxone PR and oxycodone PR doses 
as factors, an improvement was observed with decreasing 
oxycodone–naloxone ratio and appeared to plateau at the 
2:1 ratio, with the overall effect at 2:1 being approximately 
50% greater than at 4:1. Naloxone at doses of 20 and 40 mg 
improved bowel function in comparison to placebo (P,0.05). 
A trend toward an increase in diarrhea with the higher nalox-
one doses was observed, and the 2:1 oxycodone:naloxone 
ratio was identified as the most suitable.31
Oxycodone–naloxone PR renders similar analgesia and 
reverses OIC in comparison to oxycodone PR administered 
alone in patients with chronic nonmalignant pain, cancer 
patients with pain, and in patients with postoperative pain, 
and thus it improves patients’ compliance and quality of 
life.60–62
In a study by Trenkwalder et al that evaluated the efficacy 
and tolerability of oxycodone–naloxone PR in the treatment 
of RLS, the adverse-event profile was consistent with the 
safety profile of opioids.20 The most frequent adverse events 
were fatigue, constipation, nausea, headache, hyperhidrosis, 
somnolence, dry mouth, and pruritus. During the double-
blind phase, adverse events related to treatment were reported 
in 73% of the oxycodone–naloxone PR group compared to 
43% of the placebo group, while 57% of patients reported 
at least one adverse event related to treatment during the 
extension phase. The adverse events were usually mild or 
moderate in intensity. During the double-blind phase, 11% 
of patients in the oxycodone–naloxone PR group and 5% of 
placebo recipients reported severe side effects, while 9% of 
patients during the extension phase reported severe adverse 
events. Twelve (8%) of 150 patients had clinically relevant 
constipation as an adverse event during the double-blind 
phase. Three patients in the oxycodone–naloxone PR group 
during the double-blind phase and three during the extension 
phase had serious treatment-related adverse events: vomit-
ing, constipation (n=2), ileus, subileus, and acute flank pain. 
In the double-blind phase, a higher proportion of patients 
discontinued prematurely because of adverse events in the 
oxycodone–naloxone PR group than in the placebo group 
(15% vs 7%); during the extension phase, 9% discontinued 
prematurely. A follow-up visit occurred 4 weeks after the 
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physical and psychological dependence (176 patients were 
reassessed). Drug-withdrawal symptoms occurred in one 
patient after 12 weeks and in two patients after 1 year of 
treatment. No cases of augmentation were reported during 
either phase. Similarly, there were no reports of opioid abuse 
or tolerance.20
The use of oxycodone–naloxone PR is contraindicated 
in patients who are hypersensitive to the active substances 
(oxycodone or naloxone) or to any ingredient in the formu-
lation and in patients with acute abdominal illness, bowel 
obstruction, or portal circulation disturbances.34
Discussion
RLS is a common neurologic disorder, and in light of an 
increasing aging population, it is possible that RLS preva-
lence will increase in the coming years. The primary goal 
of RLS treatment is to reduce or eliminate symptoms and 
improve patient sleep and quality of life. The drugs currently 
available for the treatment of the disease do not always allow 
optimal control of symptoms, in particular in long-term treat-
ment. Augmentation is the main complication of long-term 
dopaminergic treatment, and frequently requires a reduction 
of current dopaminergic dose or a switch to nondopaminergic 
medications. Studies showed a lower incidence of augmen-
tation during long-term treatment with rotigotine than with 
pramipexole and ropinirole, supporting the hypothesis that 
the duration of action of the compound is one of the key 
features in the mechanism of augmentation.63,64 In a recent 
study, the shift from IR to extended-release (ER) pramipexole 
was effective in reducing augmentation and improved RLS 
symptoms with long-term sustained results.64 It is possible 
that the ER versions are more efficacious and better toler-
ated in the long-term. However, the efficacy and tolerability 
of ER dopamine agonists need to be confirmed in further 
longer-term studies.
In clinical practice, α
2
δ calcium-channel ligands 
(pregabalin, gabapentin, and gabapentin enacarbil) may be 
used as a starting treatment in patients with concomitant 
problems, such as comorbid pain syndrome or insomnia. 
In addition, they represent a valid alternative when augmenta-
tion occurs with dopamine agonists. A recent study compar-
ing pramipexole and pregabalin over 52 weeks has shown 
lower rates of augmentation for pregabalin, with similar or 
better long-term efficacy.65 Further longer-term comparative 
studies are needed, even considering ER dopamine agonists 
against α
2
δ ligands, to assess the main differences in effi-
cacy and augmentation. Although a substantial number of 
patients are treated with a combination of dopaminergic and 
nondopaminergic medications in clinical practice, studies 
are needed to prove the efficacy of a combination treatment 
in RLS.
Trenkwalder et al demonstrated the efficacy and toler-
ability of oxycodone–naloxone PR in the long-term treatment 
of patients with severe RLS inadequately controlled with 
previous treatment.20 This study confirmed the clinical expe-
rience of good efficacy of opioids in the treatment of RLS. 
Oxycodone–naloxone PR is approved for the second-line 
symptomatic treatment of adults with severe to very severe 
idiopathic RLS after failure of dopaminergic treatment.22 
In the study, the 16.6-point reduction on the IRLSSG severity-
rating scale sum score during the double-blind phase translates 
into a significant clinical improvement from “very severe” 
at the start of treatment to “mild” or “moderate” on average 
at the end of the double-blind phase. At the end of the exten-
sion phase, 43% of patients were considered remitters. This 
alleviation of symptoms also led to significant improvements 
in some secondary objectives, such as subjective quality of 
sleep and quality of life, during the double-blind phase and 
showed evidence of improvement in the extension phase. The 
treatment effect of oxycodone–naloxone PR was similar or 
greater than that reported in previous studies of dopaminergic 
drugs for moderate-to-severe RLS, although baseline severity 
differed in these studies. The safety profile of oxycodone–
naloxone PR was as expected for opioid treatment. Severe 
constipation was a rare but clinically significant adverse event. 
Common side effects included dizziness, somnolence, head-
ache, and fatigue, and led to treatment discontinuation in 7% 
of patients taking oxycodone–naloxone PR during the double-
blind phase. No cases of augmentation were reported.
Despite these considerations, opioids are still markedly 
underused in the treatment of RLS in situations in which 
alternative therapy either does not exist or is not effective. 
Opioids should be used at the lowest dose that relieves 
RLS symptoms. Opioids can be used as additional therapy 
to either or both dopamine agonists and α
2
δ ligands (com-
bination therapy) or can be used alone as monotherapy. 
Trenkwalder et al confirmed the efficacy of oxycodone–
naloxone PR in the treatment of severe RLS inadequately 
controlled with previous treatment.20 Further studies are 
needed to evaluate if oxycodone–naloxone PR is equally 
efficacious for first-line treatment. Moreover, long-term 
comparative studies between opioids, dopaminergic drugs, 
and α
2
δ ligands are needed.
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